ClinicalTrials.gg
CompletedNCT01375452Updated Jun 27, 2011

Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions

A Phase 1 interventional study of Letrozole in Healthy, sponsored by Dr. Reddy's Laboratories Limited. Completed. Open to female participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-27.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 69 Years
Sex
Female
01

Study summary

The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.

Read the detailed description

An Open Label, Balanced, Randomized,Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative oral bioavailability study in healthy, post menopausal women subjects under fasting conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy post menopausal women within the age range of 40 to 69 years.

  • A within 18-29.9 Kg/m2
  • The status should be confirmed by
  • Serum Estradiol concentration \<40 pg/mL.
  • Serum follicle stimulating hormone (FSH) concentration >30 IU/L.
  • No vaginal bleeding for at least 1 year.
  • Given written to participate in the study.
  • Absence of disease markers of 1 \& 2, \& C virus and RPR.
  • Absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening.
  • A normal 12-lead .
  • A normal chest X-ray (PA view) with in six months before the date of dosing.
  • Comprehension of the nature and purpose of the study and compliance with the requirement of the entire protocol.
  • No history or no evidence of /idiosyncratic reaction to Letrozole and related drugs or peanut products or other ingredients of the Letrozole formulation.
  • No history of significant systemic diseases.
  • Non-smokers.
  • No history of psychiatric disorders.
  • No donation of blood (one unit or 350 mL) within 56 days prior to study check- in.
  • No history of addiction to any recreational drug or drug dependence.
  • No participation in any clinical study within the past 56 days.
  • No receipt of any prescription drugs within 4 weeks or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations vitamins and natural products used for therapeutic benefits) within 14 days prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks.
  • No history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in.
  • No family history of neurological disorders.
  • Not consumed alcohol and xanthine containing food and beverages, (chocolates, tea, coffee or cola drinks) cigarettes and tobacco products, for at least 48 hours, prior to study check-in.
  • Not consumed grape fruit containing food or beverages (mosumbi/sweet lime) or poppy containing foods within the 7 days prior to check-in of both the periods.
  • Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Cannabinoids and Barbiturates) in urine during the each period of study check-in.
  • Negative alcohol breathe analysis during the each period of study check-in.

Exclusion criteria

Exclusion Criteria:

The subjects were excluded based on the following criteria.

  • Subjects incapable of understanding the .
  • History of suggestive of breast carcinoma, endometrial carcinoma or cervical carcinoma.
  • History of suggestive of deep vein thrombosis and/or undiagnosed vaginal bleeding.
  • History of thromboembolic disorders.
  • History of seizures.
  • History of any other major surgical procedure in the past 3 months.
  • History of diabetes mellitus and systemic hypertension.
  • Past history of anaphylaxis or angioedema.
  • History of porphyria, Dubin-Johnson, Rotor syndrome or any other hyperbilirubinemia syndrome.
  • History of otosclerosis exacerbated during pregnancy.
  • History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic,hematological, gastrointestinal, endocrine or immunological diseases.
  • Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study{one drink is equal to one unit of alcohol [one glass wine, half pint beer, and one measure (one ounce) of spirit}.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • An unusual or abnormal diet e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study, for whatever reason e.g. because of fasting due to religious reasons.
  • Any major illness in the past three months or any ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
  • If any Dysplastic changes in the Papanicolaou Smear.
  • Female volunteers demonstrating a positive pregnancy test.
  • Female volunteers who are currently breast-feeding.
  • History of problem in swallowing tablet.
  • Used an oral containing estrogens or progesterone, or any form of hormonal therapy or intake of HRT and pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 6 months of the start of the study.
  • History of habituation to coffee, tea or other xanthine containing products and inability to withhold the intake during the-in house-stay.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Femara

    Drug: Letrozole

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

  • Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited

    Also known as: Femara® Tablets 2.5 mg

06

What researchers measure

Primary outcomes

  1. Bioavailability based on Cmax and AUC parameters

    Time frame: 3 Months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 17, 2011
Start
Mar 2008
Primary completionActual
May 2008
CompletionActual
May 2008
Last update
Jun 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01375452
First posted
Jun 17, 2011
Start date
Mar 2008
Primary completion
May 2008
Completion
May 2008
Last update
Jun 27, 2011

Study contacts

A. Jaya Chandra Reddy, FRCS
principal investigator · Trident Life Sciences Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion